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Background
Despite the extensive clinical use of oxcarbazepine for
indications such as epilepsy, neuropathic pain and bipo-
lar disorders, its' effects on corticomotor excitabilility
have not been investigated in detail. We have recently
shown that the main neurophysiological effect of the drug
is an elevation of corticomotor threshold (Exp Brian Res).
Whether this effect is mediated by the parent drug or its'
metabolites is currently unknown.
To correlate the neurophysiological effects of oxcar-
bazepine on corticomotor excitability with plasma levels
of the parent drug and metabolites.
Materials and methods
Twenty patients with partial epilepsy and 10 patients suf-
fering from neuropathic pain (median age: 38 years,
range: 13–83, 11 females) were studied before and after
the administration of oxcarbazepine (mean dose: 1800
mg, range: 900–2100). TMS was performed with a Mag-
stim 200 stimulator and a figure of eight coil (recording,
FDI). Thr was measured at 1% steps using the Mills-Nithi
approach.
The quantitative analysis of oxcarbazepine (OXCBZ), 10-
hydroxy-10, 11-dihydrocarbamazepine (10OH-CBZ) and
10,11-trans-dihydroxy-10,11-dihydrocarbamazepine
(DiOH-CBZ) in plasma and CSF samples was performed
using a previously reported HPLC assay (Pienimaki et al.
1995), with slight modification. The HPLC system was
operated isocratically at a flow rate of 0.8 ml/min, the col-
umn was maintained at 35 oC and peaks were detected at
237. Quantification of oxcarbazepine and its metabolites
was determined by linear regression analysis of peak
height ratios vesrus concentrations of added analytes.
Results
Oxcarbazepine increased Thr from 42.89 ± 8.89% at base-
line to 51.21 ± 14.41% (p < 0.0001). The mean (± SD)
plasma levels of Oxc, 10OH-CBZ and DiOH-CBZ were
259 ± 294 ng/ml, 19039 ± 8263 ng/ml and 1446 ± 812
ng/ml, respectively. The change in threshold induced by
the drug was significantly correlated with the plasma lev-
els of the 10OH-CBZ (r2 = 0.36, p < 0.01). In contrast
there was no significant relationship with the levels of the
parent drug or the dixydroxy derivative.
Discussion
Oxcarbazepine, in common with other Na+ channel
blockers, increases corticomotor threshold and this neu-
rophysiological effect is mediated primarily by 10OH-
CBZ.
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